What Is Keeping Interest in Ferric Carboxymaltose Strong?
A closer look at the market reveals a few recurring themes:
Iron deficiency is being identified and treated more actively in several chronic care settings than it was in the past.
Intravenous iron products have become a familiar part of treatment discussions in many hospitals and specialty practices.
Access to infusion-based therapies is gradually improving as healthcare infrastructure expands.
Pharmaceutical companies continue to evaluate opportunities within the injectable iron segment.
Reliable API supply remains a priority as more markets gain access to ferric carboxymaltose formulations.














